In conclusion, using data from nationally representative samples of Medicare beneficiaries, we identified that the use of SGLT2 inhibitors compared with the use of DPP4 inhibitors was associated with a lower risk of AF. This evidence concerns the gene DPP4 and atrial fibrillation.